| Dr Mark Aaaron Worley, MD, PHD | |
|
2200 Fort Roots Dr, 116a-nlr, North Little Rock, AR 72114-1709 | |
| (501) 257-3478 | |
| (501) 257-3117 |
| Full Name | Dr Mark Aaaron Worley |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 32 Years |
| Location | 2200 Fort Roots Dr, North Little Rock, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255347951 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | N-8405 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. Francis House Nwa, Inc. | 0042262495 | 38 |
News Archive
Black cardiac arrest victims who are stricken outside hospitals are less likely to receive bystander CPR and defibrillation on the scene than white patients, according to research that will be presented by a research team from the Perelman School of Medicine at the University of Pennsylvania today at the annual meeting of Society for Academic Emergency Medicine.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.
The Cardiovascular Research Foundation (CRF) of New York, NY and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced today the initiation of the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) II trial and the PROSPECT ABSORB sub study.
Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.
Most products on the market today that are used to treat skin problems target the effects of the disease or wound such as inflammation, which can prolong the healing process and result in scarring. However, LSU Assistant Professor Wei Xu and collaborators at Northwestern University discovered a new way to prevent inflammation and to speed up the skin's healing process.
› Verified 5 days ago
| Entity Name | St. Francis House Nwa, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417197245 PECOS PAC ID: 0042262495 Enrollment ID: O20090526000134 |
News Archive
Black cardiac arrest victims who are stricken outside hospitals are less likely to receive bystander CPR and defibrillation on the scene than white patients, according to research that will be presented by a research team from the Perelman School of Medicine at the University of Pennsylvania today at the annual meeting of Society for Academic Emergency Medicine.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.
The Cardiovascular Research Foundation (CRF) of New York, NY and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced today the initiation of the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) II trial and the PROSPECT ABSORB sub study.
Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.
Most products on the market today that are used to treat skin problems target the effects of the disease or wound such as inflammation, which can prolong the healing process and result in scarring. However, LSU Assistant Professor Wei Xu and collaborators at Northwestern University discovered a new way to prevent inflammation and to speed up the skin's healing process.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Aaaron Worley, MD, PHD 2200 Fort Roots Dr, 116a-nlr, North Little Rock, AR 72114-1709 Ph: (501) 257-3478 | Dr Mark Aaaron Worley, MD, PHD 2200 Fort Roots Dr, 116a-nlr, North Little Rock, AR 72114-1709 Ph: (501) 257-3478 |
News Archive
Black cardiac arrest victims who are stricken outside hospitals are less likely to receive bystander CPR and defibrillation on the scene than white patients, according to research that will be presented by a research team from the Perelman School of Medicine at the University of Pennsylvania today at the annual meeting of Society for Academic Emergency Medicine.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.
The Cardiovascular Research Foundation (CRF) of New York, NY and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced today the initiation of the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) II trial and the PROSPECT ABSORB sub study.
Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.
Most products on the market today that are used to treat skin problems target the effects of the disease or wound such as inflammation, which can prolong the healing process and result in scarring. However, LSU Assistant Professor Wei Xu and collaborators at Northwestern University discovered a new way to prevent inflammation and to speed up the skin's healing process.
› Verified 5 days ago
Dr. Sandra Jean Ellis, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2200 Fort Roots Dr, North Little Rock, AR 72114 Phone: 501-257-3131 | |
Dr. Paula Irene Graham, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2200 Fort Roots Dr, North Little Rock, AR 72114 Phone: 501-257-1000 | |
Jane Jee-sun Kang, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3500 Springhill Dr Ste 100, North Little Rock, AR 72117 Phone: 501-945-8838 | |
Joshua Woolley, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2200 Fort Roots Dr, Building 170 Unit 1l, North Little Rock, AR 72114 Phone: 501-257-3324 | |
Samuel J House, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3201 Springhill Dr Ste 400, North Little Rock, AR 72117 Phone: 501-945-8838 Fax: 501-945-8835 | |
Dr. Tim Allen Kimbrell, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2200 Fort Roots Drive, Bldg 170 Unit 2h, North Little Rock, AR 72114 Phone: 501-257-3468 Fax: 501-257-3125 |